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Purpose: The primary objective of this study was to evaluate with venography the rate of
thrombus regression after a fixed dose of low–molecular weight heparin (LMWH) per
day for 3 months compared with oral anticoagulant therapy for deep venous thrombo-
sis (DVT). Secondary endpoints were the comparisons of the efficacy and safety of both
treatments.
Methods: This study was designed as an open randomized clinical study in a university hos-
pital setting. Of the 165 patients finally enrolled in the study, 85 were assigned LMWH
therapy and 80 were assigned oral anticoagulant therapy. In the group randomized to oral
anticoagulant therapy, the patients first underwent treatment in the hospital with stan-
dard unfractionated heparin and then coumarin for 3 months. Doses were adjusted with
laboratory monitoring to maintain the international normalized ratio between 2.0 and
3.0. Patients in the LMWH group were administered subcutaneous injections of fixed
doses of 40 mg enoxaparin (4000 anti-Xa units) every 12 hours for 7 days, and after dis-
charge from the hospital, they were administered 40 mg enoxaparin once daily at fixed
doses for 3 months without a laboratory control assay. A quantitative venographic score
(Marder score) was used to assess the extent of the venous thrombosis, with 0 points indi-
cating no DVT and 40 points indicating total occlusion of all deep veins. The rate of
thrombus reduction was defined as the difference in quantitative venographic scores after
termination of LMWH or coumarin therapy as compared with the scores obtained on the
initial venographic results. The efficacy was defined as the ability to prevent symptomatic
extension or recurrence of venous thromboembolism (documented with venograms or
serial lung scans). The safety was defined as the occurrence of hemorrhages.
Results: After 3 months of treatment, the mean Marder score was significantly decreased
in both groups in comparison with the baseline score, although the effect of therapy was
significantly better after LMWH therapy (49.4% reduction) than after coumarin thera-
py (24.5% reduction; P < .001). LMWH therapy and male gender were independently
associated with an enhanced resolution of the thrombus. A lower frequency of sympto-
matic recurrent venous thromboembolism was also shown in patients who underwent
treatment with LMWH therapy (9.5%) than with oral anticoagulant therapy (23.7%; P
< .05), although this difference was entirely a result of recurrence of DVT. Bleeding
complications were significantly fewer in the LMWH group than in the coumarin group
(1.1% vs 10%; P < .05). This difference was caused by minor hemorrhages. Coumarin
therapy and cancer were independently associated with an enhanced risk of complica-
tions. Subcutaneous heparin therapy was well tolerated by all patients.
Conclusion: The patients who were allocated to undergo enoxaparin therapy had a sig-
nificantly greater improvement in their quantitative venographic score, a significantly
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Low–molecular weight heparin (LMWH) has
been shown to be at least as effective and safe as intra-
venous adjusted-dose heparin in the initial treatment
of proximal deep vein thrombosis (DVT).1-10
However, common practice is to carry out treatment
with oral anticoagulants for at least 3 months as a form
of secondary prevention.11 Oral anticoagulant therapy
is associated with a significant risk of bleeding compli-
cations, and patients who undergo such therapy
require frequent laboratory monitoring. Some of these
patients have relative or absolute contraindications to
the use of oral anticoagulants.12 Under such circum-
stances, an alternative to prevent delayed thromboem-
bolic recurrence is adjusted dose of subcutaneous
heparin twice daily.11-13 Compared with unfractionat-
ed heparin, LMWH has a longer half life, significantly
fewer hemorrhagic complications, and a greater
bioavailability at low doses, which allows once-a-day
schedule and therefore may be preferable to standard
heparin especially for long-term administration.14
Some studies have recently evaluated the role of
LMWH as an alternative to oral anticoagulation in the
prevention of recurrent thromboembolism.12,15,16
They suggest that fixed doses of LMWH appear to be
quite effective and safe, but limited data on the basis of
venographic observations are available. Previous inves-
tigations that compared LMWH with standard unfrac-
tioned heparin in the initial treatment of DVT revealed
a phlebographic improvement in the patients who
underwent treatment with LMWH when the
venograms were performed approximately 1 or 2
weeks later,14 but no significant differences were seen
at the 6 month follow-up examination.17 From the
existing evidence, it is likely that a marked or total
reduction of thrombi will reduce the incidence of post-
thrombotic syndrome.18 Because a longer duration of
the treatment with LMWH may increase the success
rate of recanalization of the occluded veins, it seems
legitimate to use phlebographic endpoints.19 For this
reason, the primary objective of the present study was
to evaluate with venography the rate of thrombus
regression after a single subcutaneous injection of
LMWH (enoxaparin, 40 mg) per day for 3 months as
compared with oral anticoagulant therapy for the
treatment of patients with DVT. Secondary endpoints
were to compare the efficacy (prevention of sympto-
matic venous thromboembolism) and safety (occur-
rence of hemorrhage) of both treatments.
MATERIAL AND METHODS
Study design. This was an open, randomized
study comparing conventional coumarin therapy
with a 3-month course of enoxaparin (4000 anti-Xa
units; 40 mg) subcutaneously once daily in a fixed
dose. The primary endpoint was the ability to
reopen thromboses veins, defined as the difference
in quantitative venographic scores after termination
of LMWH or coumarin therapy compared with the
scores obtained on the initial venography. The sec-
ondary endpoints were the development of sympto-
matic recurrent pulmonary embolism or sympto-
matic recurrent venous thrombosis (documented
with serial perfusion lung scans or venograms) and
bleeding episodes. Randomization was achieved by
means of a prescribed schedule. Informed written or
verbal consent was obtained from all patients in the
study. The study protocol was accepted by the
Institutional Review Board.
Patients. Consecutive eligible patients with
clinically suspected DVT confirmed with contrast
venography were enrolled in the study according to
a computer schedule. The reasons for exclusion
were: clinically suspected pulmonary embolism, cur-
rently active bleeding or coagulation abnormality or
disorders contraindicating anticoagulant therapy,
pregnancy, two or more previously documented
episodes of DVT or pulmonary embolism, ongoing
anticoagulant treatment at the time of referral, his-
tory of heparin-induced thrombocytopenia, caval fil-
ter inserted, allergic reaction to contrast material, a
coagulation-inhibitor deficiency, a lupus anticoagu-
lant, or antiphospholipid antibodies. In each patient,
anticoagulant therapy was started as soon as possible
after DVT had been documented objectively with
ascending contrast venography. Whenever possible,
the patients were allowed to walk on the third day of
treatment, wearing elastic compressive stockings.
Regimens. In the patients randomized to oral
anticoagulant therapy, an intravenous bolus of 100
U/kg of unfractioned heparin was administered, fol-
lowed by a continuous intravenous infusion of
heparin. The activated partial thromboplastin time
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lower recurrence rate of symptomatic venous thromboembolism, and a significantly
lower incidence of bleeding than patients who underwent treatment with coumarin.
LMWH can be used on an outpatient basis as a safer and more effective alternative to
classical oral anticoagulant therapy for the secondary prophylaxis of selected patients
with DVT. (J Vasc Surg 1999;30:283-92.)
was measured 4 hours after the beginning of intra-
venous heparin treatment, and the test was repeated
at intervals of 4 to 6 hours until the result was with-
in the prescribed therapeutic range (ratio, 1.5 to
2.0) during the initial 24 hours of therapy. Oral
treatment with coumarin (initial dose of 5 mg) was
started in patients on day 5 of heparin treatment.
The coumarin dose was adjusted daily to maintain
the international normalized ratio (INR) between
2.0 and 3.0. Subsequently, heparin treatment was
discontinued and the coumarin dose was adjusted
with laboratory monitoring for 3 months. Although
during this study the classical approach to the treat-
ment of DVT was used, the results of two random-
ized clinical trials20,21 have shown that oral antico-
agulant therapy starting with heparin at the time of
diagnosis is as effective and safe as the conventional
regimen. The intensity of anticoagulation therapy in
the first 3 months was expressed as the percentage of
time during which a patient had a specific INR
(<2.0, 2.0 to 3.0, or >3.0), with this period calcu-
lated with linear interpolation. No patients under-
went oral anticoagulant therapy after 3 months of
treatment, unless they had symptomatic recurrent
thromboembolism. Patients in the LMWH group
were administered subcutaneous injections every 12
hours of fixed doses of 40 mg enoxaparin (corre-
sponding to 4000 international factor Xa inhibitory
units) for 7 days. After discharge from the hospital,
the patients underwent treatment with 40 mg
enoxaparin subcutaneously once daily, which was
usually administered by the patients themselves or
by relatives and only occasionally by nurses. LMWH
was administered at fixed doses, without a laborato-
ry control assay for 3 months.
Main outcome measures. Venography was per-
formed with long-leg films and no ionic contrast
material according to the method of Rabinov and
Paulin.22 The criteria for DVT were an intraluminal
filling defect confirmed in at least two different pro-
jections and no filling of a venous defect despite
repeated injections with contrast material. A quanti-
tative venographic score (Marder score23) was used
to assess the extent of the venous thrombosis, with
0 points indicating no DVT and 40 points indicating
total occlusion of all deep veins (Table I). Control
phlebographies were performed routinely in all
patients after 3 months of treatment. Each patient
was assigned to one of the following groups on the
basis of differences on the Marder score between ini-
tial and post-treatment phlebography: increased
thrombosis (an increase in score points), unchanged
(unaltered total score or ≤10% decrease in score
points), partly cleared (>10% to ≤50% decrease in
score points), substantially cleared (>50% to 89%
decrease in score points), and completely lysed
( ‡ 90% decrease in score points). Perfusion lung
scanning and chest radiography were performed for
all patients at baseline. To exclude bias, the assess-
ment of venograms and lung scans were scored by
two observers who were blind to treatment alloca-
tion and to the sequence in which the tests were
done (before or after treatment). The efficacy of
treatment was defined as the ability to prevent symp-
tomatic extension or recurrence of venous throm-
boembolism. The safety was defined as the occur-
rence of hemorrhages. Bleeding was defined as
major bleeding if it was intracraneal or retroperi-
toneal or if it produced a decrease in the hemoglo-
bin level of at least 2.0 g/dL, sufficient to necessi-
tate discontinuation of treatment or the transfusion
of 2 or more units of blood. Bleeding was defined as
minor bleeding if it did not meet the criteria for
major bleeding.
Surveillance and follow-up. After discharge,
all the patients were seen in our vascular clinic every
month during the first trimester and then every 3
months during a total of 1 year of follow-up. They
were instructed to come to the hospital immediate-
ly if symptoms or signs of recurrent DVT, pul-
monary embolism, or bleeding developed. Those
patients with suspected recurrent DVT underwent
contrast venography. Recurrent DVT was defined as
a constant intraluminal filling defect not present the
first day. Patients with clinically suspected pul-
monary embolism underwent another perfusion
lung scan and chest radiography. The diagnosis was
made on the basis of the presence of at least one seg-
mental defect not seen on the preceding scan and no
abnormality on the chest radiograph area. If the
results were inconclusive, pulmonary angiography
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Table I. Venographic quantitation of thrombosis
(Marder score)
Deep veins Score*
Iliac 6
Common femoral 4
Superficial femoral 10
Popliteal 4
Anterior tibial 4 (2 each)
Posterior tibial 6 (3 each)
Peroneal 6 (3 each)
*Total occlusion or nonfilling of a given vein was assigned the
maximum score; segmental occlusion or fillings defects were
given lesser scores in proportion to the degree of involvement.
was performed. During the 3 months of treatment,
platelet counts were obtained each month in the
patients undergoing LMWH therapy to rule out the
possibility of heparin-induced thrombocytopenia.
Adherence to the study regimens was monitored by
reviews of the patients’ charts. At each visit, patients
were questioned about the appearance of new symp-
toms, bleeding, swelling, heaviness of leg, leg tired-
ness, or pain. The clinical status after 3 months of
treatment was graded subjectively by each patient as
improved, unchanged, or worse in relation to the
pretreatment status.
Statistical analysis. On the basis of results from
previous trials,24 the proportion of patients with an
unchanged or improved Marder score after LMWH
treatment was assumed to be 90%. By sample size,
we determined a 15% absolute difference in the 
proportions of patients whose conditions were
unchanged and improved that were needed to show
a statistically significant difference between the two
treatments. At an 80% power for showing this dif-
ference at the 5% significance level, with a one-sided
test, a total of 78 patients would be necessary at least
in each treatment group. The number of patients
planned for inclusion into each group was therefore
92, to account for an anticipated drop-out rate of
15%. Quantitative data were expressed as mean ±
standard error. Confidence intervals (CI) of 95% for
the difference between the two treatment groups
were calculated with the normal approximation to
the binomial distribution. The rates of asymptomatic
pulmonary embolism, recurrent thromboembolism,
bleeding, death, degree of thrombus regression, and
clinical status in the two groups were compared by
means of Fisher exact test or c 2 test as appropriate.
The changes in venographic score were analyzed
within and between groups with two-sample and
matched-pair and unpaired t tests. Univariate analy-
sis was performed to identify factors that affected the
differences on the Marder score between initial and
post-treatment phlebography. A multivariate step-
wise regression model was used to identify indepen-
dent variables that could influence the percentage of
change in Marder score and complications of both
groups. Two-sided P values of less than .05 were
considered significant. Software JMP 3.1 from the
S.A.S. Institute Inc (Cary, NC) was used.
RESULTS
Patients. From June 1994 to June 1997, 257
consecutive patients with clinically suspected DVT
underwent treatment in our hospital. Eligible
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Fig 1. Venographic changes with 40 mg enoxaparin (4000 anti-Xa units). A, Total occlusion
of popliteal and femoral veins in patient with deep venous thrombosis. B, Complete recana-
lization after fixed dose per day for 3 months of treatment.
A B
patients (n = 185) had DVT confirmed with contrast
venography, perfusion lung scanning within 48
hours of study entry, and chest radiography. Of
these, 93 were assigned to undergo LMWH therapy
and 92 to undergo treatment with coumarin.
Twenty patients were excluded from the analysis
(eight in the LMWH group, and 12 in the coumarin
group) because the second venogram was not
obtained (n = 12), the regimen of treatment was not
performed correctly by the patient (n = 5), or the
patients were lost during the follow-up period (n =
3). For the 165 patients finally enrolled into the
study, the baseline clinical characteristics are shown
in the Table II. The treatment groups were compa-
rable at entry except for age (younger in the
coumarin group) and incidence of silent pulmonary
embolism (higher in the coumarin group). To assess
the possible effect of this potential age and asympto-
matic pulmonary embolism imbalance, multiple
logistic regression was used. No significant effect
was found.
Degree of thrombus regression. The intensity
of oral anticoagulant therapy in the coumarin group
was 15% with INR less than 2.0, 64% with INR from
2.0 to 3.0, and 21% with INR more than 3.0. A sec-
ond venogram was performed in all patients. The
changes in the extent of venous thrombosis on venog-
raphy are summarized in Table III. No significant dif-
ference in Marder score was observed between the
two treatment groups at inclusion. After 3 months of
treatment, the mean Marder score was significantly
decreased in both groups in comparison with the
baseline score, although the effect of therapy was sig-
nificantly better after LMWH therapy (49.4% reduc-
tion of the Marder score) than after coumarin therapy
(24.5% reduction of the Marder score; P < .001; Fig
1). The results of the stratified analysis of the evolu-
tion of the thrombus (Table III), on the basis of the
percentage of the differences of score between the ini-
tial and post-treatment phlebography, also showed a
statistically significant superiority of LMWH therapy
over coumarin therapy (P < .001).
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Table II. Clinical characteristics of patients with deep venous thrombosis treated with enoxaparin or
coumarin
Enoxaparin (n = 85) Coumarin (n = 80) P value
Mean age (years) 62.7 (r, 19 to 83) 58.3 (r, 20 to 82) <.05
Sex (male:female) 41:44 46:34
Days since onset of symptoms 4.9 (r, 1 to 30) 4.1 (r, 1 to 20)
Asymptomatic pulmonary embolism 21 (24.7%) 45 (56.2%) <.001
Risk factors to DVT
Recent trauma, surgery, or immobilization 34 (40%) 23 (28.77%)
Cancer 10 (11.7%) 8 (10%)
Unknown 41 (48.2%) 49 (61.2%)
Location of thrombus
Calf with popliteal vein 6 (7.05%) 7 (8.7%)
Popliteal and femoral vein 43 (50.5%) 35 (43.7%)
Popliteal, femoral, and iliac vein 26 (30.5%) 30 (37.5%)
Iliac vein 10 (11.7%) 8 (10%)
DVT, Deep venous thrombosis.
Table III. Venographic evaluation
Enoxaparin (n = 84)* Coumarin (n = 80) P value
Marder score
Before treatment 24.7 ± 1.1 26.06 ± 1.1
After treatment 12.5 ± 1.05 19.7 ± 1.1 <.001
Difference (D ) –12.2 ± 0.9 –6.4 ± 0.8 <.001
Fate of the thrombus <.001
Increase in size 2 (2.3%) 8 (10%)
No change 3 (3.5%) 13 (16.2%)
Partial clearance 39 (46.4%) 45 (56.2%)
Substantial clearance 24 (28.5%) 13 (16.2%)
Complete lysis 16 (19.04%) 1 (1.2%)
*One patient died of massive pulmonary embolism.
Univariate analysis shows that no significant dif-
ferences were observed in the distribution of
changes in venographic score between both groups
when the cause of DVT was cancer or the thrombus
was placed only at geniculate or iliac level (Table
IV). In contrast, a higher reopening rate of throm-
bosed veins was shown in the patients assigned to
undergo LMWH therapy as compared with the
patients assigned to undergo treatment with
coumarin when the cause of DVT was recent trau-
ma, surgery, or immobilization (P = .0037), when
the DVT was idiopathic (P = .0009), or when the
thrombus was placed in popliteal and femoral veins
(P = .0011) or affected completely all of the limb (P
= .01005). In a step-wise linear regression model,
LMWH therapy (P < .0001) and male gender (P =
.0199) were independently associated with an
enhanced resolution of the thrombus (Table V). The
r2 value was 0.11435.
Recurrent thromboembolism. Symptomatic
extension or recurrent venous thromboembolism
confirmed with objective tests developed in eight
patients (9.5%) of the LMWH group and in 19
patients (23.7%) assigned to undergo coumarin
therapy (P = .0196; Table V). Of the 19 events in
the coumarin group, 15 involved recurrent throm-
bosis (13 recurrences were in the same limb, two
were contralateral) and four involved pulmonary
embolism (from which all patients required cava fil-
ter placement). Of the eight events in the LMWH
group, five involved recurrent thrombosis (all in the
same limb) and three involved pulmonary embolism
(from which one patient died on the fifth day after
randomization). The absolute difference in the fre-
quency of pulmonary embolism did not reach statis-
tical significance (P = .7149). However, significant
differences were observed in the frequency of recur-
rent thrombosis (P = .0161). During the 12-month
surveillance period, two patients in the coumarin
group had a recurrence of symptomatic DVT docu-
mented with venography after discontinuation of
the anticoagulant treatment (one in the 20th week,
and the other in the 24th week). In the LMWH
group, three patients had symptomatic recurrent
DVT documented with venography (one in the 20th
week, another in the 24th week, and another in the
32nd week). Only one patient of the coumarin
group was readmitted to the hospital in the 21st
week because of symptomatic recurrent pulmonary
embolism confirmed with perfusion lung scanning
and chest radiography. No symptomatic pulmonary
embolisms were observed in the LMWH group.
Recurrent thromboembolism was associated with
recent surgery or trauma in three patients (three
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Table IV. Univariate analysis of risk factors and location of thrombus associated with differences on the
Marder score between initial and post-treatment phlebography
Enoxaparin D Marder score Coumarin D Marder score P value
Risk factors to DVT
Recent trauma, surgery, or immobilization 11.4 ± 1.3 6.2 ± 1.04 <.01
Cancer 8.1 ± 2.1 3.5 ± 1.5
Unknown 13.7 ± 1.5 7 ± 1.2 <.001
Location of thrombus
Calf with popliteal vein 7 ± 2.3 5.1 ± 2.2
Popliteal and femoral vein 11.8 ± 1.3 6.1 ± 1.06 <.01
Popliteal, femoral, and iliac vein 15.2 ± 2.07 8.7 ± 1.2 <.05
Iliac vein 8.3 ± 1.8 0.25 ± 4.1
D Marder score, Marder score before treatment – Marder score after treatment; DVT, deep venous thrombosis.
Table V. Independent determinants of the percentage of change in Marder score as selected with multi-
variate step-wise linear regression model
Significant independent
95% CI
variables Lower Upper F value P value
Treatment (enoxaparin) –28.329 –9.889 16.5 .0001
Sex (male) –20.348 –1.851 5.53 .0199
F, Fisher-Snedecor.
R2 = 0.11435.
cases in the LMWH group, and none in the
coumarin group), cancer in 10 patients (five cases in
the LMWH group, and five in the coumarin group),
and idiopathic disease in 20 patients (three cases in
the LMWH group, and 17 in the coumarin group).
Bleeding complications. Bleeding complica-
tions were significantly fewer in the LMWH group
(1.1% vs 10%; P = .0160; Table VI). Major bleeding
occurred during or immediately after the initial ther-
apy in one patient undergoing LMWH therapy
(1.1%) and in 2 patients undergoing treatment with
coumarin (2.5%; P = .6136). The hemorrhage in the
LMWH group consisted of upper gastrointestinal
bleeding, and in the coumarin group, there were
one upper gastrointestinal bleeding and one
retroperitoneal bleeding with hematuria. Minor
hemorrhagic complications occurred in none of the
patients who underwent LMWH therapy and in six
patients who underwent treatment with coumarin
(7.5%; P = .0121). The minor bleedings in the
coumarin group consisted of two hematuriax, three
epistaxis, and one hemoptysis. Small hematomas in
the abdominal wall were seen in patients assigned to
undergo LMWH therapy. In a step-wise logistic
regression model (Table VII), coumarin therapy
(odds ratio, 2.82; CI, 1.719 to 4.623; P < .0001)
and cancer (odds ratio, 2.15; CI, 1.101 to 4.233; P
= .025) were independently associated with an
enhanced risk of complications (symptomatic recur-
rent thromboembolism and bleeding). These con-
clusions remained unchanged when the few patients
with documented DVT who were withdrawn after
randomization because of protocol violation were
included in an intention-to-treat analysis.
Deaths. One patient from the LMWH group
died of massive pulmonary embolism, confirmed
with angiography, on the fifth day after the initial
treatment. During the 12-month study period, four
patients who were assigned to the LMWH group
died, as compared with three patients assigned to the
coumarin group. The causes of death included can-
cer (five patients) and cardiovascular disease (two
patients).
Compliance. Only one case of thrombocytope-
nia (<100.000/mm3) was observed immediately
after the initial therapy with unfractioned heparin.
This disorder dissapeared with oral anticoagulant
therapy. Subcutaneous heparin therapy was well tol-
erated by all patients. No patients showed heparin-
induced thrombocytopenia in the 3-month group
with LMWH. The clinical status graded subjectively
by each patient was significantly better after LMWH
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Table VI. Thromboembolic and bleeding complications during initial treatment and follow-up examination
Enoxaparin (n = 85) Coumarin (n = 80) P value
Treatment period (3 months)
Major bleeding 1 2
Minor bleeding 0 6 .0121
Total events 1 8 .0160
Recurrence of DVT 5 15 .0161
Pulmonary embolism 3* 4
Total events 8 19 .0196
Surveillance period (9 months)
Recurrence of DVT 3 2
Pulmonary embolism 0 1
Total events 3 3
DVT, Deep venous thrombosis.
*One fatal pulmonary embolism.
Table VII. Independent determinants of complications (venous thromboembolism and bleeding) as
selected with multivariate step-wise logistic regression model
Significant independent
95% CI
variables Lower Upper Odds ratio P value
Treatment (coumarin) 1.719 4.623 2.82 .0001
Risk factor (cancer) 1.101 4.233 2.15 .0250
CI, Confidence interval.
therapy than after coumarin therapy (P < .001).
There was an improvement after 3 months of treat-
ment in relation to the pretreatment status in 68 of
84 patients (80.9%) in the LMWH group and in 40
of 80 (50%) in the coumarin group. There were no
changes in 15 of 84 patients (17.8%) in the LMWH
group and in 35 of 80 (43.7%) in the coumarin
group. Finally, there was worsening in one of 84
patients (1.1%) and five of 80 (6.2%), respectively.
DISCUSSION
This study showed that enoxaparin, a LMWH, not
only can be used safely and effectively to treat DVT at
home for long term but also that its ability to reopen
thromboses veins is better than coumarin, an anti–vit-
amin K oral anticoagulant. Although the mean Marder
score was significantly improved in both groups at the
3-month follow-up examination, a higher degree of
recanalization was shown with venography in the
patients assigned to undergo LMWH therapy (49.4%)
as compared with the patients assigned to undergo
treatment with coumarin (24.4%). Moreover, in a
multivariate analysis, the male patients were indepen-
dently associated with an enhanced resolution of the
thrombus. A thrombus reduction of at least 30% or
more is at present used in several trials as a sign of clin-
ical benefit for the individual patient,19 with the
expectancy that a major recanalization may also result
in a reduced incidence of post-thrombotic syn-
drome.18,19 Because of this, evidence on the basis of
venographic findings suggests that a LMWH may
reduce the risk of the late sequelae of DVT, although
it will open for discussion to what extent the reduction
of thrombus size really is accomplished by long-term
benefits. The 12-month follow-up period used in this
study is too short to reflect the true development of
clinical post-thrombotic syndrome. However, LMWH
was subjectively associated by each patient with better
clinical status than coumarin therapy after 3 months of
treatment.
Long-term venographic follow-up data in
patients with DVT are limited.17 Our study is the
first to analyse a longer duration of treatment with
LMWH and the tendency of thrombus regression in
comparison with patients undergoing oral anticoag-
ulant therapy as a form of secondary prevention. The
mechanism by which LMWH facilitates thrombus
regression is not understood. Probably the inhibi-
tion of thrombin formation, the lesser risk of platelet
aggregation, and local effects at the endothelial level
play a critical role.25,26 Indeed, endothelial cells are
the principal physiologic source of tissue-type plas-
minogen activator, and the subcutaneous adminis-
tration of LMWH causes an increase in plasma of tis-
sue-type plasminogen activator with peak at 3 hours
after injection.27,28
The recanalization of thrombosed veins was quite
different in these two patient groups according to the
cause of DVT and the localization of the venous
occlusion. Particularly, there was a significant trend
in favor of LMWH when the cause of DVT was
recent trauma, surgery, or immobilization, when the
DVT was idiopathic, or when the thrombus was
placed in popliteal and femoral veins or affected com-
pletely all of the limb. By contrast, if the cause of
DVT was cancer or the intraluminal filling defect was
exclusively placed at geniculate or iliac level, no sig-
nificant differences were observed between patients
assigned to undergo LMWH therapy and patients
assigned to undergo treatment with coumarin.
Nevertheless, because of the large standard error and
the relatively small number of patients among these
subgroups, this study does not have sufficient statis-
tical power to detect significant differences. Further
studies are necessary before definitive conclusions
can be reached.
LMWH have undergone limited investigations
for the secondary prevention of venous thromboem-
bolism.9 In these studies, patients first underwent
treatment in the hospital with standard heparin, and
then therapy with LMWH was compared with thera-
py with warfarin15,16 or subcutaneous standard
heparin12 for 3 to 6 months. Monreal et al12 showed,
in a consecutive series of patients with contraindica-
tion to coumarin therapy, that patients who under-
went treatment with LMWH had a lower frequency
of either recurrent pulmonary embolism or minor
bleeding in comparison with unfractioned heparin,
although none of these differences were statistically
significant perhaps because of the small number of
patients (beta error). Pini et al15 confirmed these
findings in a sufficiently large randomized study of
patients with DVT, although the diagnosis of recur-
rent DVT was often made on the basis of noninvasive
testing and diagnosis of pulmonary embolism could
be questioned because baseline lung scans were not
performed. Despite these facts, they showed essen-
tially no difference in the incidence of recurrent
thrombosis between patients who underwent treat-
ment with LMWH (enoxaparin 40 mg) and patients
who underwent treatment with warfarin, but patients
allocated to undergo LMWH therapy had a signifi-
cantly lower incidence of bleeding. In the third trial,
which has been reported in abstract form, Kakkar16
corroborated these findings with dalteparin.
In our study, rates of symptomatic recurrent
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thromboembolism and bleeding also tended to occur
less in the patients undergoing enoxaparin therapy
than in those patients undergoing coumarin therapy
(odds ratio, 2.82; CI, 1.719 to 4.623). As expected,
a low bleeding rate was observed in the LMWH
group. The regimen of 40 mg enoxaparin, at a fixed
dose once daily subcutaneously, resulted in 1.1% ver-
sus 10% of hemorrhagic complications compared with
the coumarin treatment (P < .05). This difference was
a result of minor hemorrhages. Concomittantly, a
lower frequency of symptomatic recurrent venous
thromboembolism was shown in patients who under-
went treatment with LMWH (9.5%) than with oral
anticoagulants (23.7%; P < .05), although this differ-
ence was entirely a result of recurrence of DVT. Thus,
we find a statistically significant superiority of LMWH
over coumarin regarding both efficay and safety.
Although the doses that we used in the present study
were actually prophylactic doses rather than treatment
doses, especially for the first 7 days of treatment, it is
important to consider whether our results were
caused by a true property of enoxaparin because ade-
quate dosage finding studies are not available.29,30
The fact that a patient died in the LMWH group of a
recurrent pulmonary embolism on the fifth day of
randomization suggests that the dosage used may be
insufficient and that higher levels should be preferable
in these patients. Particularly, we believe that an
adjusted dose per kilogram of body weight would be
recommendable for the management of DVT,
although further dose-related studies are necessary to
define minimal and maximal doses.
Because the two regimens were given by different
route and because dose adjustments were necessary
in the coumarin group, we could not use a double-
blind design. To minimize bias in the assessment of
symptomatic recurrent venous thromboembolism, all
suspected recurrences were evaluated with objective
tests and the data were analyzed by two blinded
observers. Given that we did routinely screen all
patients with venography at 3 months, silent venous
recurrences may not have gone undetected, but silent
pulmonary embolism may have occurred, because
lung scans were only taken to assist diagnosis of
symptomatic pulmonary embolism. Some concern
may arise from the finding that there was a higher
frequency of silent pulmonary embolism in patients
allocated to the coumarin group than in patients allo-
cated to the LMWH group, which could have poten-
tially skewed the results. However, a multiple logistic
regression showed that this variable was not inde-
pendently associated with the recurrence of venous
thromboembolism and bleeding. In addition, both
groups were comparable according to location of
thrombus, predisposing factors, and extension of the
venous thrombosis. The higher frequency of silent
pulmonary embolism confirms previous studies 
that show that, by the time the DVT has been diag-
nosed, many patients have already had a pulmonary
embolism.31
The number of deaths and, in particular, the pro-
portion of deaths in patients with cancer (three of
five in the LMWH group, and two of three in the
coumarin group) were comparable in both treat-
ment groups. Our data therefore do not substantiate
the hypothesis that LMWH administration could
exert a favorable effect on cancer progression.1,6
However, the patients with cancer were indepen-
dently associated with more complications (odds
ratio, 2.15; CI, 1.101 to 4.233).
Regarding the compliance of the patients with
LMWH therapy, this was well tolerated and allowed
the patients to be fully ambulant. None of the
patients had negative reactions to undergoing treat-
ment at home with a subcutaneous injection daily
for 3 months, and no patients showed heparin-
induced thrombocytopenia in the 3-month group
with LMWH therapy. However, most patients had
small hematomas in the injection sites. Although
osteoporosis is a well-known side-effect of heparin
therapy, particularly in long-term therapy, we have
not performed any bone density measurements, x-
rays, or other studies to look for this potential com-
plication. According to the only study that has ana-
lyzed this fact, LMWH therapy was associated with
a lesser risk of bone fracture than unfractionated
heparin therapy.12 This means that LMWH seems to
be a good alternative to standard heparin for patients
in whom oral anticoagulant therapy is contraindicat-
ed, especially elderly patients, in whom spine frac-
tures are quite common.
In conclusion, the patients allocated to undergo
treatment with enoxaparin had a significantly greater
improvement in their clinical status and quantitative
venographic score, a significantly lower recurrence
rate of symptomatic venous thromboembolism, and a
significantly lower incidence of bleeding than patients
who underwent treatment with coumarin. These
promising results obtained with LMWH therapy
administered by subcutaneous injection, without lab-
oratory monitoring, raise the possibillity that these
agents can be used on an outpatient basis as a safer
and more effective alternative to classic oral anticoag-
ulant therapy for the secondary prophylaxis of select-
ed patients with established DVT. Particularly good
candidates would be pregnant women, patients with a
JOURNAL OF VASCULAR SURGERY
Volume 30, Number 2 Gonzalez-Fajardo et al 291
high risk of bleeding, elderly people, patients with life-
threatening diseases, and those patients in whom the
periodic monitoring is impossible because they live in
remote areas or are unable to cooperate (dementia,
chronic alcoholism, etc).
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